Preoperative plasmapheresis experience in Graves' disease patients with anti-thyroid drug-induced hepatotoxicity.

Apaydın, T; Elbasan, O; Yavuz, DİLEK

doi:10.1016/j.transci.2020.102826

Preoperative plasmapheresis experience in Graves' disease patients with anti-thyroid drug-induced hepatotoxicity.

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis, cilt.59, 2020 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 59
Basım Tarihi: 2020
Doi Numarası: 10.1016/j.transci.2020.102826
Dergi Adı: Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, Biotechnology Research Abstracts, EMBASE, MEDLINE
Anahtar Kelimeler: Hepatitis, Methimazole, Plasmapheresis, Thyrotoxicosis, PLASMA-EXCHANGE, HEPATIC-INJURY, THYROID STORM, HYPERTHYROIDISM, THERAPY, THYROTOXICOSIS, METHIMAZOLE, GUIDELINES
Marmara Üniversitesi Adresli: Evet

Özet

Hepatotoxicity is a rare but serious side effect of antithyroid drug (ATI) therapy in Graves' disease patients. Cessation of ATI drug is needed in most of the patients if liver enzymes highly elevated or in case of agranulocytosis. Permanent therapy, surgery or radioactive iodine ablation are the treatment choices to ensure euthyroidism in active Graves' disease patients.